AWL-II-38.3 is primarily utilized in research and development within the pharmaceutical industry, particularly in the study of neurological disorders. It has shown potential in modulating specific pathways associated with neurodegenerative diseases, making it a candidate for further investigation in drug discovery. Additionally, its application extends to preclinical studies where it is used to evaluate efficacy and safety in animal models. Researchers also explore its potential in targeting cellular mechanisms that could lead to the development of novel therapeutic agents.